New Treatment of Alopecia Areata

• Status: Completed
• Trial end date: 2022-10-19
• Target enrollment: 0
• Participant gender: All

Summary

Abstract: Alopecia areata is believed to be an autoimmune disease resulting from a breach in the immune privilege of the hair follicles causing non scarring hair loss.

Methods: our study included 40 patients from may 2019 to july 2022 diagnosed clinically, dermatoscopically and pathologically as alopecia areata Data were enrolled from department of dermatology and venereology, Al-Hussein hospital.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Al-Azhar University

Criteria

Inclusion Criteria:

• Alopecia areata multilocularis and alopecia totalis. Age from 16-60 years old. Ophiasis pattern alopecia areata.

Exclusion Criteria:

• Age less than 16 and more than 60years old. Alopecia areata of the face.

• Patient under treatment.